Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

Authors :: Mariana Brandão
Martine Piccart-Gebhart
Fabien Reyal
Anne-Sophie Hamy
Source :: ESMO Open, ESMO Open, 4 (3, ESMO Open, Vol 4, Iss 3 (2019)
Publication Year :: 2019
Publisher :: BMJ Publishing Group, 2019.
Abstract: SCOPUS: ed.j<br />info:eu-repo/semantics/published

Tools